Aktiesnakken — Juli 2010
-
der er mange mange andre gode aktier, så det er bestemt ikke meningen vi kun skal tale genmab, nu var det så bare sindssygt store nyheder vi
-
fik i torsdags og mange af os er ikke kommet over chokket
-
mfa, det bedste er så at holde sig fra Genmab. Det er high risk og man skal vide hvad man går ind til
-
mfa, den der står i debatten
-
-
tyske tal imorgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind